OTCMKTS:GNBTGenerex Biotechnology Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Generex Biotechnology Co. Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $0.49 0.00 (0.00 %) (As of 08/5/2020 09:44 AM ET) Add Compare Share Today's Range$0.45Now: $0.49▼$0.5350-Day Range$0.49MA: $0.58▼$0.6852-Week Range$0.14Now: $0.49▼$1.65Volume745,559 shsAverage Volume607,098 shsMarket Capitalization$38.79 millionP/E RatioN/ADividend YieldN/ABeta-2.74 ProfileAdvanced ChartCompetitorsEarningsFinancialsHeadlinesSEC FilingsSocial Media Generex Biotechnology Corporation, through its subsidiaries, primarily engages in the administration of formulations of large molecule drugs to the oral cavity using a hand-held aerosol applicator in Canada and the United States. It offers Generex Oral-lyn, an insulin formulation administered as a fine spray into the oral cavity. The company is also developing AE37, a synthetic peptide vaccine to stimulate a potent and specific immune response against tumors with low levels of expression of the HER-2/neu oncogene in patients with breast cancer and prostate cancer. In addition, it develops, manufactures, and distributes rapid point-of-care in-vitro medical diagnostics for infectious diseases, such as human immunodeficiency virus, tuberculosis, malaria, hepatitis B, hepatitis C, syphilis, and others; and cassette devices. The company has a collaboration agreement with HydRx Farms Ltd. to co-develop products for the delivery of cannabinoids via the buccal mucosa. Generex Biotechnology Corporation was founded in 1983 and is based in Miramar, Florida.Read More Beat the Market (BTM) Rank™ 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Generex Biotechnology. Previous Next 2.9 Community Rank Outperform VotesGenerex Biotechnology has received 106 “outperform” votes. (Add your “outperform” vote.)Underperform VotesGenerex Biotechnology has received 78 “underperform” votes. (Add your “underperform” vote.)Community SentimentGenerex Biotechnology has received 57.61% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Generex Biotechnology and other stocks. Vote “Outperform” if you believe GNBT will outperform the S&P 500 over the long term. Vote “Underperform” if you believe GNBT will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldGenerex Biotechnology does not currently pay a dividend.Dividend GrowthGenerex Biotechnology does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Generex Biotechnology insiders have not sold or bought any company stock.Percentage Held by Insiders35.20% of the stock of Generex Biotechnology is held by insiders. A high percentage of insider ownership can be a sign of company health. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Generex Biotechnology is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Generex Biotechnology is -1.33, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGenerex Biotechnology has a P/B Ratio of 3.73. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 0.0Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™0.78 out of 5 stars Industry, Sector and Symbol Stock Exchange OTCMKTS Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:GNBT Previous Symbol CUSIPN/A CIK1059784 Webwww.generex.com Phone416-364-2551Debt Debt-to-Equity Ratio0.45 Current Ratio0.05 Quick Ratio0.03Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$6.20 million Price / Sales6.26 Cash FlowN/A Price / Cash FlowN/A Book Value$0.13 per share Price / Book3.73Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-9,340,000.00 Net MarginsN/A Return on Equity-381.14% Return on Assets-47.82%Miscellaneous Employees3 Outstanding Shares79,940,000Market Cap$38.79 million Next Earnings Date11/10/2020 (Estimated) OptionableNot Optionable $0.49 0.00 (0.00 %) (As of 08/5/2020 09:44 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive GNBT News and Ratings via Email Sign-up to receive the latest news and ratings for GNBT and its competitors with MarketBeat's FREE daily newsletter. Generex Biotechnology (OTCMKTS:GNBT) Frequently Asked Questions How has Generex Biotechnology's stock been impacted by COVID-19 (Coronavirus)? Generex Biotechnology's stock was trading at $0.7170 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, GNBT shares have decreased by 32.3% and is now trading at $0.4853. View which stocks have been most impacted by Coronavirus. When is Generex Biotechnology's next earnings date? Generex Biotechnology is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020. View our earnings forecast for Generex Biotechnology. How were Generex Biotechnology's earnings last quarter? Generex Biotechnology Co. (OTCMKTS:GNBT) posted its quarterly earnings results on Monday, June, 22nd. The company reported ($0.07) EPS for the quarter. The company earned $0.50 million during the quarter. View Generex Biotechnology's earnings history. Has Generex Biotechnology been receiving favorable news coverage? Media coverage about GNBT stock has trended somewhat negative recently, InfoTrie Sentiment reports. The research group scores the sentiment of news coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Generex Biotechnology earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned headlines about the company a news buzz of 5.0 out of 10, meaning that recent news coverage is somewhat likely to have an effect on the company's share price in the next several days. View the latest news about Generex Biotechnology. Who are some of Generex Biotechnology's key competitors? Some companies that are related to Generex Biotechnology include Galectin Therapeutics (GALT), Harrow Health (HROW), Minerva Neurosciences (NERV), Mustang Bio (MBIO), KITOV PHARMA LT/S (KTOV), Genprex (GNPX), OASMIA PHARMACE/ADR (OASM), Eton Pharmaceuticals (ETON), ESSA Pharma (EPIX), Kindred Biosciences (KIN), CELYAD SA/ADR (CYAD), Inflarx (IFRX), Mallinckrodt (MNK), Obseva (OBSV) and Checkpoint Therapeutics (CKPT). View all competitors. What other stocks do shareholders of Generex Biotechnology own? Based on aggregate information from My MarketBeat watchlists, some companies that other Generex Biotechnology investors own include SLS International (SLS), Unilife (UNISQ), Amgen (AMGN), Novavax (NVAX), Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Quest Diagnostics (DGX), (MRNA), VBI Vaccines (VBIV) and Vaxart (VXRT). Who are Generex Biotechnology's key executives? Generex Biotechnology's management team includes the following people: Mr. Joseph Moscato, Chairman, Pres & CEO (Age 55)Mr. Mark Corrao, CFO & Treasurer (Age 64)Mr. Andrew Ro, Chief Investment Officer & Director (Age 48)Mr. Richard D. Purcell, Sr. VP of Research & Drug Devel. (Age 58)Mr. Terry R. Thompson, Chief Operating Officer (Age 61) What is Generex Biotechnology's stock symbol? Generex Biotechnology trades on the OTCMKTS under the ticker symbol "GNBT." How do I buy shares of Generex Biotechnology? Shares of GNBT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Generex Biotechnology's stock price today? One share of GNBT stock can currently be purchased for approximately $0.49. How big of a company is Generex Biotechnology? Generex Biotechnology has a market capitalization of $38.79 million and generates $6.20 million in revenue each year. Generex Biotechnology employs 3 workers across the globe. What is Generex Biotechnology's official website? The official website for Generex Biotechnology is www.generex.com. How can I contact Generex Biotechnology? Generex Biotechnology's mailing address is 10102 USA TODAY WAY, MIRAMAR FL, 33025. The company can be reached via phone at 416-364-2551 or via email at [email protected] This page was last updated on 8/5/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
